Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Naa40em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Naa40em1flox/Cya

Common Name
Naa40-flox
Product ID
S-CKO-14978
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-70999-Naa40-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Naa40-flox Mouse (Catalog S-CKO-14978) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Naa40-flox
Strain ID
CKOCMP-70999-Naa40-B6J-VA
Gene Name
Naa40
Product ID
S-CKO-14978
Gene Alias
NatD, Nat11, 4931433E08Rik
Background
C57BL/6JCya
Gene Full Name
N(alpha)-acetyltransferase 40, NatD catalytic subunit
Modification
Conditional knockout
NCBI ID
70999 (Mouse)
Phenotype
MGI:1918249
Chromosome
Chr 19 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000025675
NCBI Transcript ID
NM_027643
Target Region
Exon 2~3
Size of Effective Region
~2.3 kb
Overview of Gene Research
Naa40, or N-alpha-acetyltransferase 40, is a highly specific epigenetic enzyme. It catalyzes the transfer of an acetyl moiety to the alpha -amino group of serine 1 on histones H4 and H2A, thus playing a role in epigenetic regulation [1,3,6]. This histone N -terminal acetylation is involved in various cellular processes, including gene expression control, chromatin function, and is associated with conditions like cancer, metabolic disorders [2,7].

Depletion of Naa40 in murine hepatocytes leads to increased intracellular acetyl -CoA levels and enhanced lipid synthesis, as well as impaired insulin signalling [2]. In colorectal cancer (CRC) cells, Naa40 depletion inhibits cell proliferation and survival, increases sensitivity to 5 -Fluorouracil treatment, and delays the growth of xenograft tumors. It also reduces symmetric dimethylation of histone H4 by downregulating PRMT5, altering the expression of oncogenes and tumor suppressor genes [1]. In CRC, Naa40 controls key one -carbon metabolic genes, promotes resistance to antimetabolite chemotherapy, and its expression is associated with TYMS levels and 5 -FU response [3]. In osteosarcoma, Naa40 depletion reduces cell viability, migration, and invasion, and Naa40 contributes to tumor development by regulating AGR2 expression epigenetically [5]. In HCT116 and HT -29 colorectal cancer cells, Naa40 depletion enhances apoptosis via the mitochondrial caspase -9 -mediated apoptotic cascade in a p53 -independent manner [6].

In conclusion, Naa40 is crucial for maintaining normal cellular functions, especially in processes related to metabolism and cancer. Through gene knockout -like experiments in cells and animal models, its role in promoting cancer cell growth, metabolic regulation, and apoptosis inhibition has been revealed, making it a potential therapeutic target for cancers such as colorectal cancer, liver cancer, and osteosarcoma [1,3,4,5,6].

References:
1. Demetriadou, Christina, Pavlou, Demetria, Mpekris, Fotios, Papageorgis, Panagiotis, Kirmizis, Antonis. 2019. NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression. In Cell death & disease, 10, 236. doi:10.1038/s41419-019-1487-3. https://pubmed.ncbi.nlm.nih.gov/30858358/
2. Charidemou, Evelina, Tsiarli, Maria A, Theophanous, Andria, Griffin, Julian L, Kirmizis, Antonis. 2022. Histone acetyltransferase NAA40 modulates acetyl-CoA levels and lipid synthesis. In BMC biology, 20, 22. doi:10.1186/s12915-021-01225-8. https://pubmed.ncbi.nlm.nih.gov/35057804/
3. Demetriadou, Christina, Raoukka, Anastasia, Charidemou, Evelina, Tessarz, Peter, Kirmizis, Antonis. 2021. Histone N-terminal acetyltransferase NAA40 links one-carbon metabolism to chemoresistance. In Oncogene, 41, 571-585. doi:10.1038/s41388-021-02113-9. https://pubmed.ncbi.nlm.nih.gov/34785778/
4. Koufaris, Costas, Kirmizis, Antonis. 2021. Identification of NAA40 as a Potential Prognostic Marker for Aggressive Liver Cancer Subtypes. In Frontiers in oncology, 11, 691950. doi:10.3389/fonc.2021.691950. https://pubmed.ncbi.nlm.nih.gov/34150665/
5. Wu, Hanhua, Xu, Hua, Man, Yunan, Huang, Linhai, He, Maolin. 2025. N-terminal histone acetyltransferase NAA40 modulates osteosarcoma progression by controlling AGR2 expression. In Biochemical and biophysical research communications, 754, 151491. doi:10.1016/j.bbrc.2025.151491. https://pubmed.ncbi.nlm.nih.gov/40020320/
6. Pavlou, Demetria, Kirmizis, Antonis. . Depletion of histone N-terminal-acetyltransferase Naa40 induces p53-independent apoptosis in colorectal cancer cells via the mitochondrial pathway. In Apoptosis : an international journal on programmed cell death, 21, 298-311. doi:10.1007/s10495-015-1207-0. https://pubmed.ncbi.nlm.nih.gov/26666750/
7. Constantinou, Mamantia, Klavaris, Ariel, Koufaris, Costas, Kirmizis, Antonis. 2023. Cellular effects of NAT-mediated histone N-terminal acetylation. In Journal of cell science, 136, . doi:10.1242/jcs.260801. https://pubmed.ncbi.nlm.nih.gov/37013828/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research